Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
STAAR Surgical (NASDAQ: STAA) and activist investor Broadwood Partners entered a cooperation agreement effective January 15, 2026, after Broadwood disclosed ownership of 31% of STAAR and Yunqi Capital disclosed 6.5%. Broadwood principals Neal C. Bradsher and Richard T. LeBuhn and Christopher Wang of Yunqi joined STAAR's Board immediately, expanding the Board from six to seven members. Chair Elizabeth Yeu and Director-Board member CEO Stephen Farrell stepped down from the Board; Farrell will remain CEO until January 31, 2026. The company said the Board will announce a new Chair and CEO in the near term and will file the Cooperation Agreement as an exhibit to a Form 8-K.
Alcon (SIX/NYSE: ALC) announced on January 7, 2026 that it has terminated its definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) that was announced on August 5, 2025. The company said it remained disciplined on price and risk and that its refractive strategy is unchanged, with a continued focus on its wavelight® plus offering for LASIK.
Alcon also said it will continue global launches of more than 10 major products across surgical and vision care this year and reiterated forward-looking caution about uncertainties and risks.
Broadwood Partners, which owns 30.2% of STAAR common stock (NASDAQ: STAA), thanked shareholders after preliminary results from the January 6, 2026 Special Meeting showed a decisive vote to reject the proposed acquisition of STAAR by Alcon (NYSE: ALC). Broadwood reiterated confidence in STAAR’s standalone prospects, citing leading technology, a strong financial position, large market opportunities, and a path to margin expansion.
Broadwood said it is ready to engage with the board and fellow shareholders to implement changes aimed at improving oversight and execution to help STAAR pursue growth and profitability as an independent company.
STAAR Surgical (NASDAQ: STAA) announced preliminary results from its Special Meeting of Stockholders on January 6, 2026 showing it did not receive the required votes to approve the merger with Alcon. STAAR intends to terminate the merger agreement. No termination fee will be payable by either party. STAAR will remain a standalone, publicly traded company and continue to trade on Nasdaq under the ticker STAA. Final certified results will be filed in a Form 8-K with the SEC.
Broadwood Partners, which owns 30.2% of STAAR common stock, criticized STAAR Surgical’s fourth postponement of the shareholder vote on the proposed sale to Alcon (NYSE: ALC).
The Special Meeting was rescheduled from December 19, 2025 to January 6, 2026. Broadwood called the transaction ill-advised, urged shareholders to vote AGAINST the deal, and said several large shareholders, all three proxy advisory firms, and at least one director have expressed skepticism about the process, timing, and price.
Alcon (SIX/NYSE: ALC) has exercised its right under the merger agreement to require STAAR Surgical (NASDAQ: STAA) to adjourn its Special Meeting of Stockholders.
The Special Meeting originally set for December 19, 2025 at 8:30 a.m. Pacific Time is adjourned to January 6, 2026 at 8:30 a.m. Eastern Time. The record date for eligible STAAR stockholders remains the close of business on October 24, 2025. Stockholders with voting questions should contact STAAR's proxy solicitor, Innisfree M&A Incorporated, using the provided phone numbers for stockholders and intermediaries.
Defender Capital (long‑term STAAR shareholder, ~1.5% stake) reiterated it will vote AGAINST STAAR Surgical's proposed sale to Alcon (NYSE: ALC) and criticized the board's pursuit of the transaction. Defender called the timing and price “wrong,” noted stabilization in Q2 results, cited Broadwood Partners' engagement, and highlighted governance concerns after the company delayed the shareholder vote to December 19 and reopened bidding.
Broadwood Partners (major shareholder) sent an open letter to the STAAR Surgical board urging fellow shareholders to vote AGAINST the proposed sale to Alcon (NYSE: ALC) ahead of the special meeting scheduled for December 17, 2025. Broadwood says it owns 30.2% of STAAR, believes the deal materially undervalues the company, and pledges to cooperate with the board if the transaction fails.
Key points: Broadwood projects a path to $50 per share next year if STAAR remains independent, cites inventories normalizing in China and upcoming product launches, and calls for board leadership changes to restore shareholder confidence.
Summary not available.
Yunqi Capital, a 5.1% shareholder of STAAR (NASDAQ: STAA), urged shareholders on December 17, 2025 to reject Alcon’s amended acquisition offer of $30.75 and back STAAR’s standalone trajectory.
Yunqi said proxy adviser Glass Lewis continues to oppose the merger while ISS flipped in favor but noted shareholders could reasonably remain opposed. Yunqi criticized STAAR’s go-shop process (company engaged with 21 third parties) and highlighted upcoming catalysts including a January 2026 launch of EVO ICL V5, which the firm says could carry a 30–70% premium to existing ICL pricing.